Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 3Phase 1 3Phase NA 1Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Strabismus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Mucositis 1Lung Neoplasms 1Insulin Resistance 1Infertility, Female 1Infertility 1Hyperphagia 1Hyperglycemia 1Febrile Neutropenia 1Emergence Delirium 1

Interventions

Propofol 6Carboplatin 5Sevoflurane 4Saline Solution 3Paclitaxel 3Nivolumab 3Erlotinib Hydrochloride 3Acetaminophen 3Pemetrexed 2Midazolam 2Lidocaine 2Isoflurane 2Docetaxel 2Desflurane 2Cryotherapy 2Bupivacaine 2Bronchoscopy 2Anesthesia, Inhalation 2trametinib 1sotorasib 1pegfilgrastim 1icotinib 1endostar protein 1durvalumab 1dabrafenib 1capmatinib 1camrelizumab 1beta Carotene 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Lung Neoplasms × Injections × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡